Patterns of care and outcomes of patients with METAstatic soft tissue SARComa in a real-life setting: the METASARC observational study

[1]  P Reichardt,et al.  Soft tissue and visceral sarcomas: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

[2]  M. McCarter,et al.  Soft Tissue Sarcoma, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology. , 2016, Journal of the National Comprehensive Cancer Network : JNCCN.

[3]  E. Amir,et al.  Evolution of Randomized Trials in Advanced/Metastatic Soft Tissue Sarcoma: End Point Selection, Surrogacy, and Quality of Reporting. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  J. Blay,et al.  Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trial , 2016, The Lancet.

[5]  N. Penel,et al.  Gemcitabine-based chemotherapy in sarcomas: A systematic review of published trials. , 2016, Critical reviews in oncology/hematology.

[6]  M. McCarter,et al.  Soft Tissue Sarcoma, Version 2.2016, NCCN Clinical Practice Guidelines in Oncology. , 2016, Journal of the National Comprehensive Cancer Network : JNCCN.

[7]  D. Patt,et al.  The treatment patterns, efficacy, and safety of nab®-paclitaxel for the treatment of metastatic breast cancer in the United States: results from health insurance claims analysis , 2015, BMC Cancer.

[8]  K. S. Hall,et al.  Soft Tissue and Visceral Sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up (vol 25, pg iii102, 2014) , 2015 .

[9]  C. Teng,et al.  Optimal Sequence of Irinotecan and Oxaliplatin-Based Regimens in Metastatic Colorectal Cancer: A Population-Based Observational Study , 2015, PloS one.

[10]  S. Litière,et al.  Surrogate properties of survival endpoints in metastatic soft-tissue sarcoma: A meta-analysis. , 2015 .

[11]  K. S. Hall,et al.  Soft tissue and visceral sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

[12]  J. Blay,et al.  Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial. , 2014, The Lancet. Oncology.

[13]  J. Lee,et al.  One step forward, two steps back. , 2014, The Lancet. Oncology.

[14]  M. Schemper,et al.  Estimating the correlation of bivariate failure times under censoring , 2013, Statistics in Medicine.

[15]  G. Demetri,et al.  Clinical outcomes and safety with trabectedin therapy in patients with advanced soft tissue sarcomas following failure of prior chemotherapy: results of a worldwide expanded access program study. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

[16]  T. Treasure,et al.  Pulmonary metastasectomy for sarcoma: a systematic review of reported outcomes in the context of Thames Cancer Registry data , 2012, BMJ Open.

[17]  J. Blay,et al.  Comparison of doxorubicin and weekly paclitaxel efficacy in metastatic angiosarcomas , 2012, Cancer.

[18]  D. Dearnaley,et al.  DNA fusion-gene vaccination in patients with prostate cancer induces high-frequency CD8+ T-cell responses and increases PSA doubling time , 2012, Cancer Immunology, Immunotherapy.

[19]  J. Blay,et al.  Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial , 2012, The Lancet.

[20]  A. D. Dei Tos,et al.  Gemcitabine in advanced angiosarcoma: a retrospective case series analysis from the Italian Rare Cancer Network. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

[21]  J. Maurel,et al.  Randomized phase II study comparing gemcitabine plus dacarbazine versus dacarbazine alone in patients with previously treated soft tissue sarcoma: a Spanish Group for Research on Sarcomas study. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  P. Terrier,et al.  Feasibility of metronomic oral cyclophosphamide plus prednisolone in elderly patients with inoperable or metastatic soft tissue sarcoma. , 2011, European journal of cancer.

[23]  J. Blay,et al.  Phase II trial of weekly paclitaxel for unresectable angiosarcoma: the ANGIOTAX Study. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  G. Lyman,et al.  Dose intensity and hematologic toxicity in older cancer patients receiving systemic chemotherapy , 2005, Cancer.

[25]  M. Namer,et al.  Long-term cardiac toxicity after adjuvant epirubicin-based chemotherapy in early breast cancer: French Adjuvant Study Group results. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

[26]  P. Meltzer,et al.  Soft tissue sarcomas of adults: state of the translational science. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[27]  O. Mariani,et al.  Most Malignant Fibrous Histiocytomas Developed in the Retroperitoneum Are Dedifferentiated Liposarcomas: A Review of 25 Cases Initially Diagnosed as Malignant Fibrous Histiocytoma , 2003, Modern Pathology.

[28]  N. Kinukawa,et al.  Reassessment and clinicopathological prognostic factors of malignant fibrous histiocytoma of soft parts , 2002, Pathology international.

[29]  F. Mertens,et al.  World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of Soft Tissue and Bone , 2002 .

[30]  A. Rydholm,et al.  Clinicopathologic re-evaluation of 100 malignant fibrous histiocytomas: prognostic relevance of subclassification. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  F. Collin,et al.  Predictive value of grade for metastasis development in the main histologic types of adult soft tissue sarcomas , 2001, Cancer.

[32]  J. Blay,et al.  Randomised phase II trial of pegylated liposomal doxorubicin (DOXIL/CAELYX) versus doxorubicin in the treatment of advanced or metastatic soft tissue sarcoma: a study by the EORTC Soft Tissue and Bone Sarcoma Group. , 2001, European journal of cancer.

[33]  A. Hartz,et al.  A comparison of observational studies and randomized, controlled trials. , 2000, The New England journal of medicine.

[34]  M. van Glabbeke,et al.  Prognostic factors for the outcome of chemotherapy in advanced soft tissue sarcoma: an analysis of 2,185 patients treated with anthracycline-containing first-line regimens--a European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Study. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[35]  S. Hirota,et al.  Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. , 1998, Science.

[36]  J. Verweij,et al.  Doxorubicin versus CYVADIC versus doxorubicin plus ifosfamide in first-line treatment of advanced soft tissue sarcomas: a randomized study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[37]  C. Fletcher.  Pleomorphic Malignant Fibrous Histiocytoma: Fact or Fiction? A Critical Reappraisal Based on 159 Tumors Diagnosed as Pleomorphic Sarcoma , 1992, The American journal of surgical pathology.

[38]  C. Fletcher.  Pleomorphic Malignant Fibrous Histiocytoma: Fact or Fiction? A Critical Reappraisal Based on 159 Tumors Diagnosed as Pleomorphic Sarcoma , 1992, The American journal of surgical pathology.

[39]  J. Coindre,et al.  Soft‐tissue sarcomas of adults; study of pathological prognostic variables and definition of a histopathological grading system , 1984, International journal of cancer.